In addition to its potent 5-HT1A receptor agonism, that might be helpful in reducing dyskinetic side effects associated with the dopaminergic stimulation, such a dopaminergic profile makes DDMPA-8 a potential multitarget compound for the treatment of PD. This evidence concerns the gene HTR1A and Parkinson disease.